The roles of transporters and enzymes in hepatic drug processing

Drug Metabolism and Disposition

Volumn 33, Issue 1, 2005, Pages 1-9

  Liu, Lichuan ^a   Pang, K Sandy ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; ENALAPRILAT; LIVER ENZYME;

AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG TRANSPORT; ENZYME SUBSTRATE; FIRST PASS EFFECT; LIVER BLOOD FLOW; LIVER CELL; LIVER CELL MEMBRANE; LIVER MICROSOME METABOLISM; METABOLIC ACTIVATION; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEADY STATE; THEORETICAL MODEL; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; LIVER; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 11144276585     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001149     Document Type: Review

References (37)

1. Abu-Zahra TN and Pang KS (2000) Effect of zonal transport and metabolism on hepatic removal: enalapril hydrolysis in zonal, isolated rat hepatocytes in vitro and correlation with perfusion data. Drug Metab Dispos 28:807-813.
2. Abu-Zahra TN, Wolkoff AW, Kim RB, and Pang KS (2000) Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos 28:801-806.
3. Benet LZ and Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50 (Suppl 1):S3-S11.
4. Christians U, Jacobsen W, Benet LZ, and Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813-851.
5. Cummins CL, Jacobson W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, and Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
7. de Lannoy IA, Barker F III, and Pang KS (1993) Formed and preformed metabolite excretion clearances in liver, a metabolite formation: studies on enalapril and enalaprilat in the single pass and recirculating perfused rat liver. J Pharmacokinet Biopharm 21:395-421.
8. de Lannoy IA, Nespeca R, and Pang KS (1989) Renal handling of enalapril and enalaprilat: studies in the isolated red blood cell-perfused rat kidney. J Pharmacol Exp Ther 251:1211-1222.
9. Desai PB, Duan JZ, Zhu YW, and Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424.
10. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, and Stieger B (2000) Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32:82-86.
11. 3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 289:1134-1142.
12. Ito K, Kusuhara H, and Sugiyama Y (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res (NY) 16:225-231.
13. Johnson BM, Charman WN, and Porter CJH (2001) The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J Pharm Pharmacol 53:1611-1619.
14. Kawahara M, Sakata A, Miyashita T, Tamai I, and Tsuji A (1999) Physiologically based pharmacokinetics of digoxin in mdrIa knockout mice. J Pharm Sci 88:1281-1287.
15. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
16. Goodwin B, Redinbo MR, and Kliewer SA (2000) Regulation of cyp3a gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 42:1-23.
17. Lan LB, Dalton JT, and Schuetz EG (2000) Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58:863-869.
18. Lau YY, Wu CY, Okochi H, and Benet LZ (2004) Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 308:1040-1045.
19. Makhey VD, Guo A, Norris DA, Hu P, Yan J, and Sinko PJ (1998) Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res (NY) 15:1160-1167.
20. Morris ME and Pang KS (1987) Competition between two enzymes for substrate removal in liver: modulating effects of competitive pathways. J Pharmacokinet Biopharm 15:473-496.
21. Noé B, Hagenbuch B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350.
22. Pang KS, Cherry WF, Barker F III, and Goresky CA (1991) Esterases for enalapril hydrolysis are concentrated in the perihepatic venous region of the rat liver. J Pharmacol Exp Ther 257:294-301.
23. Pang KS, Cherry WF, Terrell JA, and Ulm EH (1984) Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos 12:309-313.
24. Pang KS and Chiba M (1994) Chapter 5: Metabolism: scaling up from in vitro to organ and whole body, in Handbook of Experimental Pharmacology (Welling PG and Balant LP eds) pp 101-187, Springer-Verlag, Stuttgart.
25. Pang KS, Chung A, Cui Y, and Keppler D (2002) Abolition of biliary excretion of enalapril and enalaprilat in EHBR perfused livers and enalapril is transported by OATP-2 and OATP-8. AAPS Annual Meeting, Nov 12-14, 2002. AAPS Pharm Sci 4:W4284. Toronto.
26. Pang KS, Wang PJ, Chung AY, and Wolkoff AW (1998) The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology 28:1341-1346.
27. Schuetz EG and Schinkel AH (1999) Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. J Biochem Mol Toxicol 13:219-222.
28. Sirianni GL and Pang KS (1997) Organ clearance concepts: new perspectives on old principles. J Pharmacokinet Biopharm 25:457-478.
29. Spareboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Bejjnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
30. Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, and Sawada Y (2000) Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 293:230-236.
31. Tam D, Sun H, and Pang KS (2003) Influence of P-glycoprotein, transfer clearances and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. Drug Metab Dispos 31:1214-1226.
32. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, and van Tellingen O (1996) Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88:994-999.
33. Wacher VJ, Silverman JA, Zhang Y, and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
34. Wu CY and Benet LZ (2003) Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine and GG918. Drug Metab Dispos 31:1292-1295.
35. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, Miyamoto K, and Tsuji A (1999) P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res (NY) 16:1213-1218.
36. Yumoto R, Murakami T, Sanemasa M, Nasu R, Nagai J, and Takano M (2001) Pharmacokinetic interaction of cytochrome P-450 3a-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone. Drug Metab Dispos 29:145-151.
37. Zahlten RN and Stratman FW (1974) The isolation of hormone sensitive rat hepatocytes by a modified enzymatic technique. Arch Biochem Biophys 163:606-608.